Management of Glioblastoma, Present and Future

Nancy Ann Oberheim Bush; Shawn L Hervey-Jumper; Mitchel S Berger

doi:10.1016/j.wneu.2019.07.044

Management of Glioblastoma, Present and Future

World Neurosurg. 2019 Nov:131:328-338. doi: 10.1016/j.wneu.2019.07.044.

Authors

Nancy Ann Oberheim Bush¹, Shawn L Hervey-Jumper¹, Mitchel S Berger²

Affiliations

¹ Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.
² Department of Neurological Surgery, University of California, San Francisco, California, USA. Electronic address: Mitchel.Berger@ucsf.edu.

PMID: 31658576
DOI: 10.1016/j.wneu.2019.07.044

Abstract

Glioblastomas are the most common malignant brain tumor and despite extensive research have a dismal prognosis. This review focuses on the current treatment paradigms of glioblastoma and highlights current advances in surgical approaches, imaging techniques, molecular diagnostics, and translational efforts. Several promising clinical trials in immunotherapy and personalized medicine are discussed and the importance of quality of life in the patients and their caregivers both during active treatment and survivorship is also commented on.

Keywords: Glioblastoma; Glioma; Immunotherapy; Pharmacology; Quality of life; Review; Targeted therapy; Treatment.

MeSH terms

Antineoplastic Agents / therapeutic use
Brain Neoplasms / diagnosis
Brain Neoplasms / therapy*
Clinical Trials as Topic
Dose Fractionation, Radiation
Female
Forecasting
Glioblastoma / diagnosis
Glioblastoma / therapy*
Humans
Immunotherapy / methods
Immunotherapy / trends
Magnetic Resonance Imaging / methods
Magnetic Resonance Imaging / trends
Male
Molecular Targeted Therapy / trends
Neurosurgical Procedures / methods
Neurosurgical Procedures / trends
Positron-Emission Tomography / methods
Positron-Emission Tomography / trends
Precision Medicine / methods
Precision Medicine / trends
Quality of Life
Risk Factors

Substances

Antineoplastic Agents